| Literature DB >> 23726662 |
M Fink1, I Letellier, M Peyrou, J P Mochel, M Jung, J N King, P Gruet, J M Giraudel.
Abstract
The purpose of this analysis was to investigate whether the recommended daily dosage of 1-2mg/kg robenacoxib provides consistent exposure when administered to dogs with chronic osteoarthritis (OA), and the need for dose adjustment in special patient populations. Data from three prospective, multi-center field studies in 208 OA dogs were analyzed using non-linear mixed effects modeling. A model based assessment was performed with stepwise inclusion and exclusion of population characteristics to explain between-subject variability, and assess the according necessity for dose adjustment. Only the influence of bodyweight on both apparent clearance and volume were found to be significant (p<0.01). No significant influence of sex, age and breed, or kidney and liver variables was identified in this representative sample of OA dogs. The population pharmacokinetic analysis performed showed that the 1-2mg/kg dosage chosen provided consistent robenacoxib exposure in a wide range of canine patients. No other dose adjustment seems necessary.Entities:
Keywords: AUC; BLQ; COX; COXIB; Dog; EBEs; FOCE; IIV; IOV; LLOQ; NSAID; OA; OFV; Population pharmacokinetics; RSE; Robenacoxib; area under the curve; below limit of quantification; cyclooxygenase; empiricial Bayes estimates; first order conditional estimation method; inter-individual variability; inter-occasion variability; lower limit of quantification; non-steroidal anti-inflammatory drug; objective function value; osteoarthritis; relative standard error
Mesh：
Substances：
Year: 2013 PMID： 23726662 DOI： 10.1016/j.rvsc.2013.04.021
Source DB: PubMed Journal: Res Vet Sci ISSN： 0034-5288 Impact factor: 2.534